Advisory Committee on Immunization Practices (ACIP), 46256-46257 [2021-17808]

Download as PDF jbell on DSKJLSW7X2PROD with NOTICES 46256 Federal Register / Vol. 86, No. 157 / Wednesday, August 18, 2021 / Notices burden of maintaining records and providing disclosures to consumers. All comments must be received on or before October 18, 2021. You can file a comment online or on paper. For the FTC to consider your comment, we must receive it on or before October 18, 2021. Write ‘‘Pay-PerCall Rule; PRA Comment: FTC File No. P072108’’ on your comment. Your comment—including your name and your state—will be placed on the public record of this proceeding, including the https://www.regulations.gov website. Due to the public health emergency in response to the COVID–19 outbreak and the agency’s heightened security screening, postal mail addressed to the Commission will be subject to delay. We encourage you to submit your comments online through the https:// www.regulations.gov website. If you prefer to file your comment on paper, write ‘‘Pay-Per-Call Rule; PRA Comment: FTC File No. P072108’’ on your comment and on the envelope, and mail your comment to the following address: Federal Trade Commission, Office of the Secretary, 600 Pennsylvania Avenue NW, Suite CC– 5610 (Annex J), Washington, DC 20580; or deliver your comment to the following address: Federal Trade Commission, Office of the Secretary, Constitution Center, 400 7th Street SW, 5th Floor, Suite 5610 (Annex J), Washington, DC 20024. If possible, submit your paper comment to the Commission by courier or overnight service. Because your comment will become publicly available at https:// www.regulations.gov, you are solely responsible for making sure that your comment does not include any sensitive or confidential information. In particular, your comment should not include any sensitive personal information, such as your or anyone else’s Social Security number; date of birth; driver’s license number or other state identification number, or foreign country equivalent; passport number; financial account number; or credit or debit card number. You are also solely responsible for making sure that your comment does not include any sensitive health information, such as medical records or other individually identifiable health information. In addition, your comment should not include any ‘‘trade secret or any commercial or financial information which . . . . is privileged or confidential’’—as provided by Section 6(f) of the FTC Act, 15 U.S.C. 46(f), and FTC Rule 4.10(a)(2), 16 CFR 4.10(a)(2)— including in particular competitively sensitive information such as costs, VerDate Sep<11>2014 17:34 Aug 17, 2021 Jkt 253001 sales statistics, inventories, formulas, patterns, devices, manufacturing processes, or customer names. Comments containing material for which confidential treatment is requested must be filed in paper form, must be clearly labeled ‘‘Confidential,’’ and must comply with FTC Rule 4.9(c). In particular, the written request for confidential treatment that accompanies the comment must include the factual and legal basis for the request, and must identify the specific portions of the comment to be withheld from the public record. See FTC Rule 4.9(c). Your comment will be kept confidential only if the General Counsel grants your request in accordance with the law and the public interest. Once your comment has been posted publicly at www.regulations.gov, we cannot redact or remove your comment unless you submit a confidentiality request that meets the requirements for such treatment under FTC Rule 4.9(c), and the General Counsel grants that request. The FTC Act and other laws that the Commission administers permit the collection of public comments to consider and use in this proceeding, as appropriate. The Commission will consider all timely and responsive public comments that it receives on or before October 18, 2021. For information on the Commission’s privacy policy, including routine uses permitted by the Privacy Act, see https://www.ftc.gov/site-information/ privacy-policy. Josephine Liu, Assistant General Counsel for Legal Counsel. [FR Doc. 2021–17662 Filed 8–17–21; 8:45 am] BILLING CODE 6750–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES Centers for Disease Control and Prevention [Docket No. CDC–2021–0089] Advisory Committee on Immunization Practices (ACIP) Centers for Disease Control and Prevention (CDC), Department of Health and Human Services (HHS). ACTION: Notice of meeting and request for comment. AGENCY: In accordance with the Federal Advisory Committee Act, the Centers for Disease Control and Prevention (CDC), announces the following meeting of the Advisory Committee on Immunization Practices (ACIP). This meeting is open to the SUMMARY: PO 00000 Frm 00083 Fmt 4703 Sfmt 4703 public. The meeting will be webcast live via the World Wide Web. A notice of this ACIP meeting has also been posted on CDC’s ACIP website at: https:// www.cdc.gov/vaccines/acip/. In addition, CDC has sent notice of this ACIP meeting by email to those who subscribe to receive email updates about ACIP. DATES: The meeting will be held on August 24, 2021, from 10:00 a.m. to 5:00 p.m., EDT (dates and times subject to change), see the ACIP website for updates: https://www.cdc.gov/vaccines/ acip/. The public may submit written comments from August 18, 2021 through August 24, 2021. ADDRESSES: You may submit comments, identified by Docket No. CDC–2021– 0089 by any of the following methods: • Federal eRulemaking Portal: https://www.regulations.gov. Follow the instructions for submitting comments. • Mail: Centers for Disease Control and Prevention, 1600 Clifton Road NE, MS H24–8, Atlanta, Georgia 30329– 4027, Attn: August 24, 2021 ACIP Meeting. Instructions: All submissions received must include the Agency name and Docket Number. All relevant comments received in conformance with the https://www.regulations.gov suitability policy will be posted without change to https://www.regulations.gov, including any personal information provided. For access to the docket to read background documents or comments received, go to https://www.regulations.gov. FOR FURTHER INFORMATION CONTACT: Stephanie Thomas, ACIP Committee Management Specialist, Centers for Disease Control and Prevention, National Center for Immunization and Respiratory Diseases, 1600 Clifton Road NE, MS–H24–8, Atlanta, Georgia 30329– 4027; Telephone: (404) 639–8367; Email: ACIP@cdc.gov. SUPPLEMENTARY INFORMATION: In accordance with 41 CFR 102–3.150(b), less than 15 calendar days’ notice is being given for this meeting due to the exceptional circumstances of the COVID–19 pandemic and rapidly evolving COVID–19 vaccine development and regulatory processes. A notice of this ACIP meeting has also been posted on CDC’s ACIP website at: https://www.cdc.gov/vaccines/acip/ index.html. In addition, CDC has sent notice of this ACIP meeting by email to those who subscribe to receive email updates about ACIP. Purpose: The committee is charged with advising the Director, CDC, on the use of immunizing agents. In addition, under 42 U.S.C. 1396s, the committee is mandated to establish and periodically E:\FR\FM\18AUN1.SGM 18AUN1 Federal Register / Vol. 86, No. 157 / Wednesday, August 18, 2021 / Notices jbell on DSKJLSW7X2PROD with NOTICES review and, as appropriate, revise the list of vaccines for administration to vaccine-eligible children through the Vaccines for Children (VFC) program, along with schedules regarding dosing interval, dosage, and contraindications to administration of vaccines. Further, under provisions of the Affordable Care Act, section 2713 of the Public Health Service Act, immunization recommendations of the ACIP that have been approved by the Director of the Centers for Disease Control and Prevention and appear on CDC immunization schedules must be covered by applicable health plans. Matters To Be Considered: The agenda will include discussions on additional doses of COVID–19 vaccine, including booster doses. Agenda items are subject to change as priorities dictate. For more information on the meeting agenda visit https://www.cdc.gov/vaccines/acip/ meetings/meetings-info.html. Meeting Information: The meeting will be webcast live via the World Wide Web; for more information on ACIP please visit the ACIP website: https:// www.cdc.gov/vaccines/acip/. Public Participation Interested persons or organizations are invited to participate by submitting written views, recommendations, and data. Please note that comments received, including attachments and other supporting materials, are part of the public record and are subject to public disclosure. Comments will be posted on https://www.regulations.gov. Therefore, do not include any information in your comment or supporting materials that you consider confidential or inappropriate for public disclosure. If you include your name, contact information, or other information that identifies you in the body of your comments, that information will be on public display. CDC will review all submissions and may choose to redact, or withhold, submissions containing private or proprietary information such as Social Security numbers, medical information, inappropriate language, or duplicate/ near duplicate examples of a mass-mail campaign. CDC will carefully consider all comments submitted into the docket. Written Public Comment: Written comments must be received on or before August 24, 2021. Oral Public Comment: This meeting will include time for members of the public to make an oral comment. Oral public comment will occur before any scheduled votes including all votes relevant to the ACIP’s Affordable Care Act and Vaccines for Children Program roles. Priority will be given to VerDate Sep<11>2014 17:34 Aug 17, 2021 Jkt 253001 individuals who submit a request to make an oral public comment before the meeting according to the procedures below. Procedure for Oral Public Comment: All persons interested in making an oral public comment at the August 24, 2021, ACIP meeting must submit a request at https://www.cdc.gov/vaccines/acip/ meetings/ no later than 11:59 p.m., EDT, August 22, 2021, according to the instructions provided. If the number of persons requesting to speak is greater than can be reasonably accommodated during the scheduled time, CDC will conduct a lottery to determine the speakers for the scheduled public comment session. CDC staff will notify individuals regarding their request to speak by email by 12:00 p.m., EDT, August 23, 2021. To accommodate the significant interest in participation in the oral public comment session of ACIP meetings, each speaker will be limited to 3 minutes, and each speaker may only speak once per meeting. The Director, Strategic Business Initiatives Unit, Office of the Chief Operating Officer, Centers for Disease Control and Prevention, has been delegated the authority to sign Federal Register notices pertaining to announcements of meetings and other committee management activities, for both the Centers for Disease Control and Prevention and the Agency for Toxic Substances and Disease Registry. Kalwant Smagh, Director, Strategic Business Initiatives Unit, Office of the Chief Operating Officer, Centers for Disease Control and Prevention. [FR Doc. 2021–17808 Filed 8–16–21; 4:15 pm] BILLING CODE 4163–18–P DEPARTMENT OF HEALTH AND HUMAN SERVICES Centers for Disease Control and Prevention Notice of Award of a Single-Source Grant To Fund Task Force for Global Health, Inc. Centers for Disease Control and Prevention (CDC), Department of Health and Human Services (HHS). ACTION: Notice. AGENCY: The Centers for Disease Control and Prevention (CDC), located within the Department of Health and Human Services (HHS) announces the award of approximately $47,000,000 in COVID–19 funding with an expected total funding of $100,000,000 over a five-year period to the Task Force for SUMMARY: PO 00000 Frm 00084 Fmt 4703 Sfmt 4703 46257 Global Health to expand the influenza and COVID–19 vaccine coverage in lowand middle-income countries. DATES: The period for this award will be September 30, 2021 through September 29, 2026. FOR FURTHER INFORMATION CONTACT: Archana Kumar, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, 1600 Clifton Road NE, MS– H24–8, Atlanta, GA 30329, Telephone: 800–232–6348, E-Mail: eocevent445@ cdc.gov. SUPPLEMENTARY INFORMATION: The single-source award will introduce and/ or expand influenza vaccine programs, contribute to evidence base for influenza control and prevention, and leverage efforts to deploy pandemic vaccines to low- and middle-income countries. The Task Force for Global Health will be awarded as a single-source because of their specific experience collaborating with multiple partners in facilitating the use of influenza vaccines in low- to middle-income countries and in developing local and global evidence base for sustained use of lifesaving vaccines since 2014. The Task Force for Global Health is uniquely qualified to support countries to plan for, implement and evaluate COVID–19 vaccination programs since they are currently working with the same risk groups using established tools and platforms under an existing cooperative agreement. The Task Force for Global Health leads the Partnership for Influenza Vaccine Introduction which includes ministries of health from 15 countries, private industry, and the United Nations International Children’s Emergency Fund. This Partnership creates sustainable, seasonal influenza vaccination programs in the targeted countries, works with the World Health Organization to prepare for pandemic influenza, and supports countries’ efforts to control and prevent seasonal outbreaks. Summary of the Award Recipient: The Task Force For Global Health. Purpose of the Award: The purpose of award is to expand the use of influenza and COVID–19 vaccines in low- and middle-income countries (LMICs), support influenza vaccine introduction through a public-private partnership, establish an evidence base for global vaccine introduction decisions, and leverage this partnership to support readiness for and deployment of future pandemic vaccines. The recipient will be expected to assist partner countries E:\FR\FM\18AUN1.SGM 18AUN1

Agencies

[Federal Register Volume 86, Number 157 (Wednesday, August 18, 2021)]
[Notices]
[Pages 46256-46257]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2021-17808]


=======================================================================
-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

[Docket No. CDC-2021-0089]


Advisory Committee on Immunization Practices (ACIP)

AGENCY: Centers for Disease Control and Prevention (CDC), Department of 
Health and Human Services (HHS).

ACTION: Notice of meeting and request for comment.

-----------------------------------------------------------------------

SUMMARY: In accordance with the Federal Advisory Committee Act, the 
Centers for Disease Control and Prevention (CDC), announces the 
following meeting of the Advisory Committee on Immunization Practices 
(ACIP). This meeting is open to the public. The meeting will be webcast 
live via the World Wide Web. A notice of this ACIP meeting has also 
been posted on CDC's ACIP website at: https://www.cdc.gov/vaccines/acip/. In addition, CDC has sent notice of this ACIP meeting by 
email to those who subscribe to receive email updates about ACIP.

DATES: The meeting will be held on August 24, 2021, from 10:00 a.m. to 
5:00 p.m., EDT (dates and times subject to change), see the ACIP 
website for updates: https://www.cdc.gov/vaccines/acip/. The 
public may submit written comments from August 18, 2021 through August 
24, 2021.

ADDRESSES: You may submit comments, identified by Docket No. CDC-2021-
0089 by any of the following methods:
     Federal eRulemaking Portal: https://www.regulations.gov. 
Follow the instructions for submitting comments.
     Mail: Centers for Disease Control and Prevention, 1600 
Clifton Road NE, MS H24-8, Atlanta, Georgia 30329-4027, Attn: August 
24, 2021 ACIP Meeting.
    Instructions: All submissions received must include the Agency name 
and Docket Number. All relevant comments received in conformance with 
the https://www.regulations.gov suitability policy will be posted 
without change to https://www.regulations.gov, including any personal 
information provided. For access to the docket to read background 
documents or comments received, go to https://www.regulations.gov.

FOR FURTHER INFORMATION CONTACT: Stephanie Thomas, ACIP Committee 
Management Specialist, Centers for Disease Control and Prevention, 
National Center for Immunization and Respiratory Diseases, 1600 Clifton 
Road NE, MS-H24-8, Atlanta, Georgia 30329-4027; Telephone: (404) 639-
8367; Email: [email protected].

SUPPLEMENTARY INFORMATION: In accordance with 41 CFR 102-3.150(b), less 
than 15 calendar days' notice is being given for this meeting due to 
the exceptional circumstances of the COVID-19 pandemic and rapidly 
evolving COVID-19 vaccine development and regulatory processes. A 
notice of this ACIP meeting has also been posted on CDC's ACIP website 
at: https://www.cdc.gov/vaccines/acip/. In addition, CDC has 
sent notice of this ACIP meeting by email to those who subscribe to 
receive email updates about ACIP.
    Purpose: The committee is charged with advising the Director, CDC, 
on the use of immunizing agents. In addition, under 42 U.S.C. 1396s, 
the committee is mandated to establish and periodically

[[Page 46257]]

review and, as appropriate, revise the list of vaccines for 
administration to vaccine-eligible children through the Vaccines for 
Children (VFC) program, along with schedules regarding dosing interval, 
dosage, and contraindications to administration of vaccines. Further, 
under provisions of the Affordable Care Act, section 2713 of the Public 
Health Service Act, immunization recommendations of the ACIP that have 
been approved by the Director of the Centers for Disease Control and 
Prevention and appear on CDC immunization schedules must be covered by 
applicable health plans.
    Matters To Be Considered: The agenda will include discussions on 
additional doses of COVID-19 vaccine, including booster doses. Agenda 
items are subject to change as priorities dictate. For more information 
on the meeting agenda visit https://www.cdc.gov/vaccines/acip/meetings/meetings-info.html.
    Meeting Information: The meeting will be webcast live via the World 
Wide Web; for more information on ACIP please visit the ACIP website: 
https://www.cdc.gov/vaccines/acip/.

Public Participation

    Interested persons or organizations are invited to participate by 
submitting written views, recommendations, and data. Please note that 
comments received, including attachments and other supporting 
materials, are part of the public record and are subject to public 
disclosure. Comments will be posted on https://www.regulations.gov. 
Therefore, do not include any information in your comment or supporting 
materials that you consider confidential or inappropriate for public 
disclosure. If you include your name, contact information, or other 
information that identifies you in the body of your comments, that 
information will be on public display. CDC will review all submissions 
and may choose to redact, or withhold, submissions containing private 
or proprietary information such as Social Security numbers, medical 
information, inappropriate language, or duplicate/near duplicate 
examples of a mass-mail campaign. CDC will carefully consider all 
comments submitted into the docket.
    Written Public Comment: Written comments must be received on or 
before August 24, 2021.
    Oral Public Comment: This meeting will include time for members of 
the public to make an oral comment. Oral public comment will occur 
before any scheduled votes including all votes relevant to the ACIP's 
Affordable Care Act and Vaccines for Children Program roles. Priority 
will be given to individuals who submit a request to make an oral 
public comment before the meeting according to the procedures below.
    Procedure for Oral Public Comment: All persons interested in making 
an oral public comment at the August 24, 2021, ACIP meeting must submit 
a request at https://www.cdc.gov/vaccines/acip/meetings/ no later than 
11:59 p.m., EDT, August 22, 2021, according to the instructions 
provided.
    If the number of persons requesting to speak is greater than can be 
reasonably accommodated during the scheduled time, CDC will conduct a 
lottery to determine the speakers for the scheduled public comment 
session. CDC staff will notify individuals regarding their request to 
speak by email by 12:00 p.m., EDT, August 23, 2021. To accommodate the 
significant interest in participation in the oral public comment 
session of ACIP meetings, each speaker will be limited to 3 minutes, 
and each speaker may only speak once per meeting.
    The Director, Strategic Business Initiatives Unit, Office of the 
Chief Operating Officer, Centers for Disease Control and Prevention, 
has been delegated the authority to sign Federal Register notices 
pertaining to announcements of meetings and other committee management 
activities, for both the Centers for Disease Control and Prevention and 
the Agency for Toxic Substances and Disease Registry.

Kalwant Smagh,
Director, Strategic Business Initiatives Unit, Office of the Chief 
Operating Officer, Centers for Disease Control and Prevention.
[FR Doc. 2021-17808 Filed 8-16-21; 4:15 pm]
BILLING CODE 4163-18-P
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.